1. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials 
Dr Jacob A Udell, MD, Matthew A Cavender, MD, Prof Deepak L Bhatt, MD, Saurav Chatterjee, MD, Prof Michael E Farkouh, MD, Benjamin M Scirica, MD 
The Lancet Diabetes & Endocrinology 
Volume 3, Issue 5, Pages (May 2015)
DOI: /S (15)
Copyright © 2015 Elsevier Ltd Terms and Conditions

2. Figure 1 Study flow diagram
The Lancet Diabetes & Endocrinology 2015 3, DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

3. Figure 2
Risk of heart failure events with glucose-lowering drugs or strategies versus standard care
Determined with an inverse-variance random-effects model.
The Lancet Diabetes & Endocrinology 2015 3, DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

4. Figure 3
Risk of heart failure events with glucose-lowering drugs or strategies versus standard care, stratified by strategy or drug class
Determined with an inverse-variance random-effects model. PPAR=peroxisome proliferator-activated receptor. DPP=dipeptidyl peptidase.
The Lancet Diabetes & Endocrinology 2015 3, DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

5. Figure 4
Risk of MACE with glucose-lowering drugs or strategies versus standard care
Determined with an inverse-variance random-effects model. MACE=major adverse cardiovascular events.
The Lancet Diabetes & Endocrinology 2015 3, DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

6. Figure 5
Major adverse cardiovascular events and individual cardiovascular events with glucose-lowering drugs or strategies versus standard care
Determined with an inverse-variance random-effects model.
The Lancet Diabetes & Endocrinology 2015 3, DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

7. Figure 6 Relation between weight gain and heart failure
Slope of the regression line is +0·0298, which after exponentiation, translates into a 7·1% (95% CI 1·0–13·6) relative greater risk for heart failure for every 1·0 kg increase in weight between glucose-lowering drugs or strategies versus standard care (p=0·022).
The Lancet Diabetes & Endocrinology 2015 3, DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions